

ASSIGNMENT

For valuable consideration, the receipt of which is hereby acknowledged, and intending to be bound legally **Fusion Antibodies PLC**, formed under the laws of the country of Northern Ireland and having a principal place of business at **Springbank Industrial Estate, 1 Springbank Road, Dunmurry, Belfast BT17 0QL, Northern Ireland** (the “Assignor”), assigns **Amunix Pharmaceuticals, Inc.**, a corporation formed under the laws of the State of Delaware and having a principal place of business at **500 Ellis Street Mountain View, CA 94003, USA**, and its successors, transferees, and assignees (collectively the “Assignee”), all of its rights, titles, and interests throughout the world in the invention(s) (the “Subject Matter”) disclosed or claimed in the patents and applications listed in Schedule A (the “Patents and Applications”).

This Assignment assigns, in addition to the Subject Matter, (a) the Patents and Applications and all other applications that may be made for, and all patents, utility models, design registrations, and other rights of exclusion and inventors’ certificates for, any of the Subject Matter (collectively the “Patents, Applications, and Granted Rights”) in every country or region, and under every treaty or convention, (b) the right to claim priority based on and the benefit of the filing date of any of the Patents, Applications, and Granted Rights under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, the Hague Agreement and all other applicable treaties or conventions, and (c) the right to pursue, collect, and retain in the Assignee’s name or otherwise, damages and any other remedies arising from any past, present, or future infringement of the Subject Matter, the Patents, Applications, and Granted Rights, and any other rights assigned by this Assignment.

To the extent any portion of the rights assigned by this Assignment has previously been assigned to the Assignee, this Assignment is a confirmation of the previous Assignment.

Assignor authorizes the Assignee to apply for and pursue protection for any or all of the Subject Matter, the Patents, Applications, and Granted Rights, and any other rights assigned by this Assignment in all countries, regions, and territories of the world, in the Assignor’s name or in the Assignee’s name.

Assignor represents and warrants that it has the right and power to make this Assignment and that it has not made and will not make any other assignment that conflicts with this Assignment.

Assignor will communicate to the Assignee (or at the request of the Assignee to other parties) all known facts in any form relating to the Subject Matter, will execute and provide all oaths and declarations, statements, testimony, assignments, powers of attorney, applications, and documents, and will perform all other lawful acts necessary or desirable to secure fully to the Assignee the rights, titles, and interests assigned by this Assignment.

Fusion Antibodies PLC (the "Assignor")

Signed at BELFAST U.K. on this 10th day of JUNE, 2024.
(City, State and Nation)

By: R. Buick

Print Name: RICHARD BUICK

Title: CHIEF SCIENTIFIC OFFICER

Amunix Pharmaceuticals, Inc. (the "Assignee") hereby acknowledges and accepts the foregoing assignment.

Signed at _____ on this _____ day of _____, 2024.
(City, State and Nation)

By: _____

Name: Lisa Rasmussen

Title: Authorized Representative,
Lead for Patent Operations U.S.

SCHEDULE A

<u>Title: COMPOSITIONS TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND METHODS FOR MAKING AND USING THE SAME</u>			
<u>Pat./Pub. No.</u>	<u>App. No.</u>	<u>Country</u>	<u>Filing Date</u>
	18/438,106	US	02/09/2024
	PCT/US2024/015223	WO	02/09/2024
	P240100320	AR	02/09/2024
	113105370	TW	02/15/2024

ASSIGNMENT

For valuable consideration, the receipt of which is hereby acknowledged, and intending to be bound legally **Fusion Antibodies PLC**, formed under the laws of the country of Northern Ireland and having a principal place of business at **Springbank Industrial Estate, 1 Springbank Road, Dunmurry, Belfast BT17 0QL, Northern Ireland** (the “Assignor”), assigns **Amunix Pharmaceuticals, Inc.**, a corporation formed under the laws of the State of Delaware and having a principal place of business at **500 Ellis Street Mountain View, CA 94003, USA**, and its successors, transferees, and assignees (collectively the “Assignee”), all of its rights, titles, and interests throughout the world in the invention(s) (the “Subject Matter”) disclosed or claimed in the patents and applications listed in Schedule A (the “Patents and Applications”).

This Assignment assigns, in addition to the Subject Matter, (a) the Patents and Applications and all other applications that may be made for, and all patents, utility models, design registrations, and other rights of exclusion and inventors’ certificates for, any of the Subject Matter (collectively the “Patents, Applications, and Granted Rights”) in every country or region, and under every treaty or convention, (b) the right to claim priority based on and the benefit of the filing date of any of the Patents, Applications, and Granted Rights under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, the Hague Agreement and all other applicable treaties or conventions, and (c) the right to pursue, collect, and retain in the Assignee’s name or otherwise, damages and any other remedies arising from any past, present, or future infringement of the Subject Matter, the Patents, Applications, and Granted Rights, and any other rights assigned by this Assignment.

To the extent any portion of the rights assigned by this Assignment has previously been assigned to the Assignee, this Assignment is a confirmation of the previous Assignment.

Assignor authorizes the Assignee to apply for and pursue protection for any or all of the Subject Matter, the Patents, Applications, and Granted Rights, and any other rights assigned by this Assignment in all countries, regions, and territories of the world, in the Assignor’s name or in the Assignee’s name.

Assignor represents and warrants that it has the right and power to make this Assignment and that it has not made and will not make any other assignment that conflicts with this Assignment.

Assignor will communicate to the Assignee (or at the request of the Assignee to other parties) all known facts in any form relating to the Subject Matter, will execute and provide all oaths and declarations, statements, testimony, assignments, powers of attorney, applications, and documents, and will perform all other lawful acts necessary or desirable to secure fully to the Assignee the rights, titles, and interests assigned by this Assignment.

Fusion Antibodies PLC (the "Assignor")

Signed at _____ on this _____ day of _____, 2024.
(City, State and Nation)

By: _____

Print Name: _____

Title: _____

Amunix Pharmaceuticals, Inc. (the "Assignee") hereby acknowledges and accepts the foregoing assignment.

Signed at Cambridge, MA US on this 11 day of June, 2024.
(City, State and Nation)

By: 

Name: Lisa Rasmussen

Title: Authorized Representative,
Lead for Patent Operations U.S.

SCHEDULE A

[illegible]